Dosage and Administration of Olaparib

Dosage and Administration of Olaparib

Olaparib is available as oral tablets, each containing 150 mg. The standard dosage is 300 mg (two tablets) twice daily, for a total daily dose of 600 mg. The two doses should be taken approximately 12 hours apart, with or without food. Tablets must be swallowed whole and should not be chewed, crushed, dissolved, or split. For patients with early breast cancer who are hormone receptor‑positive, hormone therapy should be continued during treatment with olaparib. For patients with prostate cancer who are receiving a gonadotropin‑releasing hormone analogue, this treatment should be continued unless bilateral orchiectomy (surgical castration) has been performed. The duration of treatment is determined by the physician based on the patient’s condition and tolerability; for early breast cancer, one year of treatment is generally recommended. Do not change the dose or stop treatment on your own.

Missed Dose, Overdose, and Dietary Restrictions for Olaparib

If you miss a dose of olaparib, take your next dose at the regularly scheduled time; do not take an extra dose to make up for the missed one. If you take an overdose, contact your doctor immediately or go to the nearest emergency room. During treatment with olaparib, you must avoid consuming grapefruit, grapefruit juice, Seville oranges, and their juices, as these fruits can interfere with drug metabolism, leading to abnormally high blood levels of olaparib and increasing the risk of toxicity. Additionally, you should inform your doctor of all medications you are taking, including prescription drugs, over‑the‑counter medicines, vitamins, and herbal supplements, as some drugs may affect the efficacy of olaparib or worsen side effects.

Olaparib Use in Special Populations

Before taking olaparib, be sure to tell your doctor about all your medical conditions: whether you have any lung or kidney disease, and whether you are pregnant, planning to become pregnant, or breastfeeding. Olaparib may harm an unborn baby or cause miscarriage. Women of childbearing potential must use effective contraception during treatment and for 6 months after the last dose, and should have a pregnancy test before starting treatment. Male patients with female partners should also use contraception during treatment and for 3 months after the last dose, and should not donate sperm. Breastfeeding women should not breastfeed during treatment and for 1 month after the last dose. It is important to maintain open communication with your doctor: ask about treatment expectations, keep track of how you feel, and promptly report any travel plans or changes in your life. If you experience any serious symptoms (such as difficulty breathing, signs of blood clots, jaundice, etc.), seek medical attention immediately.